NCT05116774 - BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

September 14, 2023

Study Completion Date

September 14, 2023

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG

Eculizumab

Administered by intravenous infusion per current dose regimen

DRUG

Ravulizumab

Administered by intravenous infusion per current dose regimen

DRUG

BCX9930

Administered orally twice daily

Trial Locations (7)

Investigative Site, Paris

Investigative Site, Budapest

Investigative Site, Rome

Investigative Site, Barcelona

Investigative Site, Valencia

Investigative Site, Leeds

Investigative Site, London